HK1052920B - 含氮基團的轉化方法 - Google Patents

含氮基團的轉化方法 Download PDF

Info

Publication number
HK1052920B
HK1052920B HK03104934.8A HK03104934A HK1052920B HK 1052920 B HK1052920 B HK 1052920B HK 03104934 A HK03104934 A HK 03104934A HK 1052920 B HK1052920 B HK 1052920B
Authority
HK
Hong Kong
Prior art keywords
dox
cytotoxic
group
nitrogen
mol
Prior art date
Application number
HK03104934.8A
Other languages
English (en)
Chinese (zh)
Other versions
HK1052920A1 (en
Inventor
A‧V‧沙利
A‧A‧纳吉
R-Z‧凯
A‧A‧納吉
R-Z‧凱
Original Assignee
图莱尼教育基金管理处
圖萊尼教育基金管理處
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1052920(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 图莱尼教育基金管理处, 圖萊尼教育基金管理處 filed Critical 图莱尼教育基金管理处
Publication of HK1052920A1 publication Critical patent/HK1052920A1/xx
Publication of HK1052920B publication Critical patent/HK1052920B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK03104934.8A 1995-11-27 2003-07-09 含氮基團的轉化方法 HK1052920B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
US08/562,652 1995-11-27

Publications (2)

Publication Number Publication Date
HK1052920A1 HK1052920A1 (en) 2003-10-03
HK1052920B true HK1052920B (zh) 2005-03-04

Family

ID=24247176

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104934.8A HK1052920B (zh) 1995-11-27 2003-07-09 含氮基團的轉化方法

Country Status (27)

Country Link
US (2) US5843903A (enExample)
EP (2) EP1384710B1 (enExample)
JP (2) JP3987575B2 (enExample)
KR (2) KR100467899B1 (enExample)
CN (2) CN1137136C (enExample)
AT (2) ATE401305T1 (enExample)
AU (1) AU709539B2 (enExample)
BR (1) BR9611647B1 (enExample)
CA (2) CA2238574C (enExample)
CZ (1) CZ297297B6 (enExample)
DE (2) DE69637604D1 (enExample)
DK (2) DK1384710T3 (enExample)
EA (1) EA001372B1 (enExample)
ES (2) ES2310222T3 (enExample)
HK (1) HK1052920B (enExample)
HU (1) HU229870B1 (enExample)
IL (3) IL119691A (enExample)
IS (2) IS2178B (enExample)
MX (1) MX9804119A (enExample)
NO (2) NO324035B1 (enExample)
NZ (1) NZ322054A (enExample)
PL (3) PL191781B1 (enExample)
PT (2) PT1384710E (enExample)
SK (2) SK284672B6 (enExample)
UA (1) UA67722C2 (enExample)
WO (1) WO1997019954A1 (enExample)
ZA (1) ZA969709B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
IL142869A0 (en) 1998-11-13 2002-03-10 Cyclacel Ltd Transport vectors
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
CA2388844A1 (en) * 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
EP1452543A3 (en) * 2000-04-26 2005-08-03 BioSynthema, Inc RGD (ARG-GLY-ASP) coupled to (neuro)peptides
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
IL160993A0 (en) * 2001-09-21 2004-08-31 Univ Tulane Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2003074551A2 (en) 2002-03-01 2003-09-12 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
JP5000848B2 (ja) * 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US20040043052A1 (en) 2002-05-24 2004-03-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for coating medical implants
DE60325240D1 (de) 2002-09-26 2009-01-22 Angiotech Int Ag Perivaskuläre hüllen
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
RU2361876C2 (ru) * 2003-04-22 2009-07-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. Пептидные векторы
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
US20080132458A1 (en) * 2004-03-10 2008-06-05 Threshold Pharmaceuticals, Inc. Hypoxia-Activated Anti-Cancer Agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
RU2377247C2 (ru) * 2007-12-27 2009-12-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты)
WO2009099741A1 (en) * 2008-02-01 2009-08-13 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
ES2655243T3 (es) * 2008-04-11 2018-02-19 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Derivados antibióticos de antraciclina con alta actividad, métodos de preparación y usos de los mismos
AU2009235897B2 (en) * 2008-04-11 2012-04-12 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof
MX2011000509A (es) 2008-07-15 2011-04-05 Genentech Inc Conjugados derivados de antraciclina, proceso para su preparacion y su uso como compuestos antitumorales.
CA2752608A1 (en) 2009-02-20 2010-08-26 Ipsen Pharma S.A.S. Cytotoxic conjugates having neuropeptide y receptor binding compound
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
KR101897307B1 (ko) 2010-12-02 2018-09-10 네르비아노 메디칼 사이언시스 에스.알.엘. 모르폴리닐 안트라사이클린 유도체의 제조 방법
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
KR102062025B1 (ko) * 2014-06-30 2020-01-03 타베다 세라퓨틱스, 인코포레이티드 표적화된 콘주게이트 및 입자 및 그것의 제형
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
WO2017075495A1 (en) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
CA3118743A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
AU2023239751A1 (en) 2022-03-25 2024-09-05 Provincial Health Services Authority Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
EP0434960B1 (en) * 1989-12-19 1996-09-18 PHARMACIA S.p.A. Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
ES2075244T3 (es) * 1990-04-06 1995-10-01 Univ Tulane Analogos de la somatostatina.
DE69112684T2 (de) * 1990-04-06 1996-02-01 Univ Tulane LHRH-Analoge.
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
CZ135798A3 (cs) 1998-10-14
IS2634B (is) 2010-06-15
IL134685A0 (en) 2001-04-30
JP2000502055A (ja) 2000-02-22
KR20040037176A (ko) 2004-05-04
NO20051111L (no) 2005-03-01
BR9611647B1 (pt) 2010-03-09
CA2471775A1 (en) 1997-06-05
CZ297297B6 (cs) 2006-11-15
ES2205067T3 (es) 2004-05-01
SK284392B6 (sk) 2005-03-04
CN1137136C (zh) 2004-02-04
ATE401305T1 (de) 2008-08-15
HUP9903771A2 (hu) 2000-02-28
HU229870B1 (en) 2014-10-28
IS8567A (is) 2006-11-09
SK62898A3 (en) 1999-06-11
PL326865A1 (en) 1998-10-26
US5843903A (en) 1998-12-01
PL187230B1 (pl) 2004-06-30
CN1166597C (zh) 2004-09-15
IL134685A (en) 2002-12-01
EA001372B1 (ru) 2001-02-26
IS2178B (is) 2006-12-15
AU709539B2 (en) 1999-09-02
DK0863917T3 (da) 2004-01-19
BR9611647A (pt) 1999-02-23
JP4778405B2 (ja) 2011-09-21
JP2007045845A (ja) 2007-02-22
KR100445754B1 (ko) 2004-12-08
CA2238574A1 (en) 1997-06-05
PT863917E (pt) 2004-02-27
DK1384710T3 (da) 2008-11-17
EP1384710A1 (en) 2004-01-28
HK1052920A1 (en) 2003-10-03
HUP9903771A3 (en) 2000-07-28
NO982252L (no) 1998-05-15
CN1202903A (zh) 1998-12-23
DE69637604D1 (de) 2008-08-28
ZA969709B (en) 1997-08-25
CA2238574C (en) 2004-10-19
DE69630233T2 (de) 2004-08-05
ATE251179T1 (de) 2003-10-15
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
NO982252D0 (no) 1998-05-15
CN1405127A (zh) 2003-03-26
EA199800492A1 (ru) 1998-12-24
JP3987575B2 (ja) 2007-10-10
IS4734A (is) 1998-05-05
KR19990071672A (ko) 1999-09-27
UA67722C2 (en) 2004-07-15
HK1017363A1 (en) 1999-11-19
US6184374B1 (en) 2001-02-06
EP0863917B1 (en) 2003-10-01
NZ322054A (en) 1999-04-29
IL119691A0 (en) 1997-02-18
PL191781B1 (pl) 2006-07-31
ES2310222T3 (es) 2009-01-01
AU7572296A (en) 1997-06-19
IL119691A (en) 2002-02-10
NO324035B1 (no) 2007-07-30
WO1997019954A1 (en) 1997-06-05
PL188786B1 (pl) 2005-04-29
CA2471775C (en) 2008-01-29
EP0863917A1 (en) 1998-09-16
PT1384710E (pt) 2008-10-08
DE69630233D1 (de) 2003-11-06
SK284672B6 (sk) 2005-08-04
EP1384710B1 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
CN1166597C (zh) 含氮基团的转化方法
CN1230442C (zh) 5位和6位修饰的促性腺素释放激素拮抗剂
CN1098274C (zh) 氮杂环己肽化合物
CN1203090C (zh) 环化粘合抑制剂
CN1055700C (zh) 治疗用肽衍生物
CN1182153C (zh) 新的多拉抑放素衍生物及其制备方法和用途
CN1138335A (zh) 具有生长激素释放特性的化合物
CN1095724A (zh) 新型肽，其制备及应用
CN1100426A (zh) 溶酶体酶可裂解的抗肿瘤药物组合物
CN1406124A (zh) 鼻给药的环肽组合物
CN1649625A (zh) 治疗剂或细胞毒性剂与生物活性肽的偶联物
CN1738650A (zh) 改进的胃泌素释放肽化合物
CN1514843A (zh) 生长激素释放抑制因子-多巴胺嵌合类似物
CN1541102A (zh) 生长激素抑制素激动剂
HK1046867A1 (zh) 作為光學診斷用造影劑的短鏈肽-染料結合物
CN1777439A (zh) 生长抑素的载体
CN1099040A (zh) 线性粘合抑制剂
CN1051914A (zh) 肽类
CN1367793A (zh) 神经调节肽b和生长抑素受体拮抗剂
CN1305496A (zh) 环状促生长素抑制素类似物
CN1278734A (zh) 用于治疗类风湿性关节炎的方法和组合物
CN1252728A (zh) 多拉司他汀－15衍生物与紫杉烷的组合
CN1043939A (zh) 制备抗菌素太可普劳宁的63-羧酸酰胺的方法
HK1017363B (en) Targeted cytotoxic anthracycline analogs
CN1237979A (zh) 构象限定的lh－rh类似物及其用途和含有它们的药物组合物

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

Free format text: FORMER OWNER(S): ZENTARIS AG

PE Patent expired

Effective date: 20161113